Reunion, a sentinel island for multidrug-resistant bacteria surveillance in South-western Indian ocean: a retrospective survey using hospitalised patients screening, 2015-2017

CURRENT STATUS: UNDER REVIEW

Noellie Gay
CIRAD
gnoellie@hotmail.comCorresponding Author

Nathalie Lugagne
Centre Hospitalier Universitaire de la Reunion

Guillaume Miltgen
Centre Hospitalier Universitaire de la Reunion

Olivier Belmonte
Centre Hospitalier Universitaire de la Reunion

Eric Cardinale
CIRAD

DOI:
10.21203/rs.3.rs-15589/v1

SUBJECT AREAS
Health Policy

KEYWORDS
Epidemiology, hospital, Indian Ocean, multidrug resistance, screening, colonization
Abstract

Background

Since 2015, antimicrobial resistance was identified as a public health priority for the Southwestern Indian ocean (SWIO) (Comoros, Madagascar, Mauritius, Mayotte (France), Reunion (France), and Seychelles). However, multidrug-resistant Bacteria (MRB) colonization rates in human populations from most islands of SWIO were still unknown in 2020 with neither hospital nor community baseline colonization rates estimated.

Methods

Based on exhaustive hospital MRB screening laboratory data, we provided the first estimation of MRB colonization rates in hospitalized patients residing in SWIO (2015-2017). Using Reunion (European Union) MRB colonization rate as a baseline we identified at risk patients according to their territory of residence.

Results

The survey pointed out significantly higher overall MRB colonization rates in patients from Comoros, Madagascar, Mayotte, and Seychelles when compared to Reunion (France) with extended-spectrum betalactamase producing Enterobacteriaceae as a generalized public health issue for these territories. Specific epidemiological dynamics were pointed out in Mayotte and Seychelles patients with significantly higher methicillin-resistant Staphylococcus aureus (MRSA) colonization rates; and in Mauritius patients with higher carbapenemase producing Enterobacteriaceae (CPE) colonization rate.

Conclusion

These results could be the first step to set up a regional MRB surveillance in SWIO hospitals.

Background

Since the 90’s, an increase of the prevalence of multidrug-resistant bacteria (MRB) was observed in Reunion (France).\textsuperscript{1} Epidemiological surveillance at Reunion hospitals pointed similar incidence trends as in main France territory in 2015 (\textit{i.e.} Occitanie region) for extended-spectrum betalactamase producing Enterobacteriaceae (ESBL-E) and lower incidence for methicillin-resistant \textit{Staphylococcus aureus} (MRSA).\textsuperscript{2}
Southwestern Indian Ocean (SWIO) is composed of islands (Union of Comoros, Madagascar, Mauritius, Mayotte (France), Reunion (France), and Seychelles). Based on literature, extended-spectrum betalactamase producing Enterobacteriaceae (ESBL-E) and carbapenemase producing Enterobacteriaceae (CPE) were identified as a main public and veterinary health issue for SWIO.\textsuperscript{3} Antimicrobial resistance was considered as a main public health priority for the area since 2015. However, the absence of MRB surveillance network in other SWIO territories and scarce publications on the topic prevented from identifying most affected islands and to implement targeted action plans. Felix-Guyon University hospital, in Reunion, is well suited for medical evacuations and receives most of the evacuated patients from the territories of SWIO. Since 2015, a MRB screening strategy for all patients residing abroad, arriving through medical evacuation, visiting a foreign country within the three preceding months, and/or hospitalized abroad in the past year was implemented. Furthermore, in Felix-Guyon hospital all intensive care admitted patients are screened in order to avoid introduction of MRB in the unit.

Based on exhaustive laboratory data, we estimated the prevalence of MRB colonization in hospitalized patients residing in SWIO (i.e. ESBL-E, CPE, MRSA, vancomycin-resistant enterococci, and both multidrug-resistant \textit{Acinetobacter} sp., and \textit{Pseudomonas} sp.). This study provided the first estimation of the MRB colonization rates in patients from SWIO territories using a comparable design setting.

**Methods**

**Data collection, inclusion criteria, and statistical analyses**

We performed a retrospective survey on all patients admitted to the Felix-Guyon University hospital in Reunion from 2015 to 2017 (main hospital). Only SWIO residing patients were included. All these patients were screened for MRB detection (i.e. anal and nasal swabbing) and patients admitted to intensive care unit were used as baseline for odds ratio estimation as all patients from Reunion intensive care were screened.

The MRB included were MRSA, ESBL-E, carbapenemase-producing Enterobacteriaceae (CPE), vancomycin-resistant enterococci (VRE), and both multidrug-resistant \textit{Acinetobacter} sp. (AB), and \textit{Pseudomonas} sp. as defined by Magiorakos et al.\textsuperscript{4}
A patient was considered MRB positive if carrier of one, or more than one MRB. MRB colonization rates in patients were compared according to their country of residence using $\chi^2$ test with Fisher correction or Fisher exact test if theoretical frequency were less than 5. Odds ratio were calculated with Reunion patients as reference and threshold was set at p-values <0.05. Confidence intervals were estimated using the Woolf method. The statistical analyses were performed using R software version 3.4.2. The study was approved by the French national commission on data protection and liberties (reference 2210228 v0, 10th of January 2019).

**Bacterial isolates and antibiotic susceptibility testing**

Bacterial isolates were routinely obtained at hospital laboratory and species identified for all isolates using MALDI-TOF mass spectrometry (Bruker Daltonics, Breme, Germany). ESBL-E, and CPE were screened using two selective chromogenic agar ChromID-ESBL and ChromID CARBA SMART (bioMérieux, Marcy l’Étoile, France). ESBL-E phenotypes were confirmed using combined disk synergy testing.

Gram-positive bacteria (MRSA and VRE) were detected using respectively Chrom-ID MRSA SMART and Chrom-ID VRE agar (bioMérieux, Marcy l’Étoile, France). Multidrug-resistant *Acinetobacter* sp. (MRA) and *Pseudomonas* sp. (MRP) were identified using additionally Drigalski agar plate with ceftazidime disk. All MRB were checked by antibiogram using disc diffusion method according to the European Committee on Antimicrobial Susceptibility Testing 2015 recommendations. CPE and VRE were all confirmed by PCR using the GenXpert system (Cepheid, Sunnyvale, USA).

**Results**

From the 1st of January 2015 to the 31st of December 2017, a total of 4,135 hospitalized patients from SWIO territories were included in the survey. Overall 23.7% (978/4,135) of patients were found positive for MRB colonization.

If the number of hospitalized patients according to their territory of residence varied widely (from 13 in Seychelles to 2,184 in Reunion), high MRB colonization rates were observed for patients residing in Seychelles and Madagascar (61.5% and 41.3% respectively) (Figure 1). Among all MRB positive patients, 94.4% (923/978) were ESBL-E carriers. MRB colonization rates varied according to the
MRB colonized patients were significantly higher in SWIO (excluding Mauritius patients) when compared to patients from Reunion as a baseline, ESBL-E colonization rates followed the same trend (Table 1). MRSA colonization rates were significantly higher in Seychelles and Mayotte hospitalized patients than in Reunion patients. CPE colonization rates were significantly higher in patients residing in Mauritius when compared to Reunion patients.

**Table 1.** Comparison of MRB colonization rates according to the patient’s territory of residence (2015-2017) using Reunion (France) as reference

| Patients (n) | OR (95% CI) | Prevalence (95% CI) | OR (95% CI) | Prevalence |
|-------------|-------------|---------------------|-------------|------------|
| **Seychelles** | 13          | 7.4 [2.4-22.6] **  | 61.5% [35.5%-82.3%] | 7.4 [2.4-22.6] ** | 61.5% [35.1%] |
| **Madagascar** | 322         | 3.1 [2.4-3.9] *    | 41.3% [36.1%-46.8%] | 3.1 [2.4-3.9] ** | 40.1% [34.1%] |
| **Comores** | 30          | 2.3 [1.1-5.0] *    | 33.3% [19.2%-51.2%] | 2.3 [1.1-5.0] *    | 33.3% [19.3%] |
| **Mayotte** | 1,475       | 1.7 [1.4-1.9] **   | 26.4% [24.3%-28.8%] | 1.5 [1.3-1.8] **   | 24.7% [22.1%] |
| **Mauritius** | 111         | 1.6 [1.1-2.5] *    | 26.1% [18.9%-35.0%] | 1.1 [0.7-1.8]    | 19.8% [13.1%] |
| **Reunion** b | 2,184       | 1 (ref)            | 18.7% [17.1%-20.4%] | 1 (ref) | 17.9% [16.1%] |

MRB: multidrug-resistant bacteria; ESBL-E: Extended-Spectrum Betalactamase producing Enterobacteriaceae; MRSA: Methicillin-resistant *Staphylococcus aureus*; CPE: carbapenemases-producing Enterobacteriaceae; **p<0.001; *p<0.05; ABR, PYO, and VRE were not presented as none of the IOC hospitalized patients were significantly more carriers.

**Discussion**

This study pointed out significantly higher MRB colonization rates in hospitalized patients from Comoros, Madagascar, Mayotte and Seychelles when compared to patients from Reunion. ESBL-E seems to be a generalized sanitary issue for SWIO whereas specific epidemiological trends were observed for MRSA and CPE. Higher MRSA colonization rates were reported in Mayotte and Seychelles patients and high CPE colonization rate was identified in Mauritius residing patients (p<0.001). These
results could be the first step of a regional hospital-based MRB surveillance as expected by the Indian
ocean commission since 2015.6

Our survey was based on the biggest sample size of SWIO individuals ever reported in the literature.
The study design is based on a convenience sample accordingly individuals included in analysis are
not randomly selected; this selection bias was used to explore MRB colonization in SWIO hospitals
based on the knowledge that i) patient residence country is a known risk factor for MRB infection and
carriage7-10 and that ii) individuals included in the study were probably looking for care on Reunion
after treatment in facilities of their home countries. Thus, MRB colonization rates estimated probably
approximates the MRB epidemiological situation regarding in local hospitals. However, socio-
economic status of patients seeking care on Reunion (probable people with higher incomes than the
general local population) should favor access to healthcare, medicine, and hygiene and thus probably
underestimate MRB colonization in local health care settings; poverty identified as a risk factor of MRB
colonization.11 Furthermore, use of intensive care unit patient’s screening as reference data could
over-estimate odds ratio as fewer Reunion patients should have been hospitalized in the preceding
months (risk factor for MRB acquisition12) when compared to other SWIO patients. Thus, Reunion
intensive care unit were a probable estimate of the community-acquired MRB. Finally, the small
number of hospitalized patients from Seychelles and Comoros could limit our interpretations.
If ESBL-E occurrence in IOC was already highlighted as a public health issue both in community and
hospitals3, our analysis confirmed it quantitatively. For instance, ESBL-E colonization rate estimated in
Madagascar was high (40.1%) which is in accordance with traveler’s colonization rates reported in the
literature ranging from 33.3% (1/3)13 to 57.1% (4/7)14 in 2013-2013 but higher than the ESBL-E
colonization of 18.5% reported in community in 2013-201415. High CPE colonization rate of
repatriated patients from Mauritius was already reported16 which could confirm CPE circulation in
Mauritius hospitals and/or community. Important fluxes of travelers from India were probably
contributing to MRB epidemiological changes in Mauritius as NDM-producing isolates are considered
endemic in India. Finally, comparisons of MRB colonization rates for specific MDR (i.e. MRA, MRP) were difficult to provide in other SWIO territories and Mayotte as no data were available.

**Conclusion**

Our study offered the first cartography of MDR colonization in SWIO. MDR colonization might constitute a risk of introduction in another country healthcare system. Reunion is a medically attractive territory which could provide the first MRB hospital-based surveillance for SWIO. The suitability of this regional MRB surveillance system should be confirmed.

**Abbreviations**

MDR: multidrug-resistant bacteria;

SWIO: Southwestern Indian ocean

ESBL-E: extended-Spectrum Betalactamase producing Enterobacteriaceae

MRSA: methicillin-resistant *Staphylococcus aureus*

CPE: carbapenemases-producing Enterobacteriaceae

MRA: multidrug-resistant *Acinetobacter* sp.

VRE: vancomycin-resistant enterococci.

MRP: multidrug-resistant *Pseudomonas* sp.

**Declarations**

**Ethics declaration**

**Ethics approval and consent to participate**

The presented work was carried out with the approval of the French Commission for Data Protection (Commission Nationale de l’Informatique et des Libertés) under the reference 2210228 v0, 10th of January 2019. None research ethics committee nor consent by individuals were required for this study as this was routinely collected and anonymized according to the Rectificatif au règlement (UE) 2016/679 du Parlement européen et du Conseil du 27 avril 2016 relatif à la protection des personnes physiques à l’égard du traitement des données à caractère personnel et à la libre circulation de ces données, et abrogeant la directive 95/46/CE (règlement général sur la protection des données) JOUE L127 2 du 23/05/2018.

**Consent for publication**
Not applicable.

**Availability of data and materials**

The data were obtained from Felix-Guyon hospital laboratory, Saint Denis, La Réunion. Data were provided for the survey according to the French law (reference 2210228 v0, 10th of January 2019) but are not publicly available.

**Competing interest**

The authors declare that they have no competing interests.

**Funding**

This project was ordered and funded by the Indian Ocean Health Agency (Noellie Gay PhD fellowship).

**Contributions**

NG conceived the study. NG, OB and EC defined the study methods. OB, GM, NL provided the database. NG performed the analyses and drafted the manuscript. All authors provided comments and approved the final version of the manuscript.

**Acknowledgements**

Laurent Filleul from Santé Publique France for study design and methodology advices.

**References**

1. Belmonte O, Drouet D, Alba J, Moiton MP, Kuli B, Lugagne-Delpon N, et al. Evolution of Enterobacteriaceae resistance to antibiotics in Reunion Island: emergence of extended-spectrum beta-lactamases. Pathol Biol. 2010;58: 18-24.

2. Surveillance des bactéries multirésistantes dans les établissements de santé en France. Réseau BMR-Raisin, France. Résultats 2015. Saint Maurice: Santé publique France; 2017. 112p. Available at: http://invs.santepubliquefrance.fr/Publications-et-outils/Rapports-et-syntheses/Maladies-infectieuses/2017/Surveillance-des-bacteries-multiresistantes-dans-les-etablissements-de-sante-en-France. Accessed March 18, 2018.

3. Gay N, Belmonte O, Collard JM, Halifa M, Issack MI, Mindjae S, et al. Review of
antibiotic resistance in the Indian Ocean Commission: a human and animal health issue. Front Public Health. 2017;5: 162.

4. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18: 268-281.

5. Comité de l’antibiogramme de la Société Française de Microbiologie. Société Française de Microbiologie. 2015. Available at: http://www.sfm-microbiologie.org/UserFiles/files/casfm/CASFM_EUCAST_V1_2015.pdf. Accessed December 12, 2018.

6. Rapport Annuel 2015. Commission de l’Océan Indien. Port Saint Louis. 2015. Available at: http://commissionoceanindien.org/fileadmin/resources/SG/Rapport%20annuel%202015.pdf. Accessed January 15, 2020.

7. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62: 34-42.

8. Manns BJ, Fanning EA, Cowie RL. Antituberculosis drug resistance in immigrants to Alberta, Canada, with tuberculosis, 1982-1994. Int J Tuberc Lung Dis. 1997;1: 225-230.

9. Laifer G, Widmer AF, Simcock M, Bassetti S, Trampuz A, Frei R, et al. TB in low-Incidence Country: Differences Between New Immigrants, Foreign-Born Residents and Native Residents. Am J Med. 2007;120: 350-356.

10. Bryce A, Costelloe C, Hawcroft C, Wootton M, Hay AD. Faecal carriage of antibiotic resistant Escherichia coli in asymptomatic children and associations with primary
10

care antibiotic prescribing: a systematic review and meta-analysis. BMC Infect Dis. 2016;16: 359.

11. Herindrainy P, Randrianirina F, Ratovoson R, Ratsima Hariniana E, Buisson Y, Genel N, et al. Rectal carriage of extended-spectrum beta-lactamase-producing gram-negative bacilli in community settings in Madagascar. PLoS One. 2011;6: e22738.

12. Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis. 2004;23: 163-167.

13. 1 Arcilla MS, van Hattem JM, Haverkate MR, Bootsma MCJ, van Genderen PJJ, Goorhuis A, et al. Import and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae by international travellers (COMBAT study): a prospective, multicentre cohort study. Lancet Infect Dis. 2017;17: 78-85.

14. Ruppé E, Armand-Lefèvre L, Estellat C, Consigny PH, El Mniai A, Boussadia Y, et al. High Rate of Acquisition but Short Duration of Carriage of Multidrug-Resistant Enterobacteriaceae After Travel to the Tropics. Clin Infect Dis. 2015;61: 593-600.

15. Chereau F, Herindrainy P, Garin B, Huynh BT, Randrianirina F, Padget M, et al. Colonization of extended-spectrum-beta-lactamase- and NDM-1-producing Enterobacteriaceae among pregnant women in the community in a low-income country: a potential reservoir for transmission of multiresistant Enterobacteriaceae to neonates. Antimicrob Agents Chemother. 2015;59: 3652-3655.

16. Holman AM, Allyn J, Miltgen G, Lugagne N, Traversier N, Picot S, et al.. Surveillance of carbapenemase-producing Enterobacteriaceae in the Indian Ocean Region between January 2010 and December 2015. Med Mal Infect. 2017;47: 333-339.

17. Dortet L, Cuzon G, Nordmann P. Dissemination of carbapenemase-producing Enterobacteriaceae in France, 2012. J Antimicrob Chemother. 2014;69: 623-627.
MRB colonization rates according to the patient country of residence in Indian ocean. * A MRB positive patient could be carrier of more than one MRB; MRB: multidrug-resistant bacteria; ESBL-E: extended-Spectrum Betalactamase producing Enterobacteriaceae; MRSA: methicillin-resistant Staphylococcus aureus; CPE: carbapenemases-producing Enterobacteriaceae; MRA: multidrug-resistant Acinetobacter sp.; VRE: vancomycin-resistant enterococci.; MRP: multidrug-resistant Pseudomonas sp.